 Neuroblastoma
"Neuroblastoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Descriptor ID |
D009447
|
| MeSH Number(s) |
C04.557.465.625.600.590.650.550 C04.557.470.670.590.650.550 C04.557.580.625.600.590.650.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neuroblastoma".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Neoplasms, Germ Cell and Embryonal [C04.557.465]
- Neuroectodermal Tumors [C04.557.465.625]
- Neoplasms, Neuroepithelial [C04.557.465.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.465.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.465.625.600.590.650]
- Neuroblastoma [C04.557.465.625.600.590.650.550]
- Neoplasms, Glandular and Epithelial [C04.557.470]
- Neoplasms, Neuroepithelial [C04.557.470.670]
- Neuroectodermal Tumors, Primitive [C04.557.470.670.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.470.670.590.650]
- Neuroblastoma [C04.557.470.670.590.650.550]
- Neoplasms, Nerve Tissue [C04.557.580]
- Neuroectodermal Tumors [C04.557.580.625]
- Neoplasms, Neuroepithelial [C04.557.580.625.600]
- Neuroectodermal Tumors, Primitive [C04.557.580.625.600.590]
- Neuroectodermal Tumors, Primitive, Peripheral [C04.557.580.625.600.590.650]
- Neuroblastoma [C04.557.580.625.600.590.650.550]
Below are MeSH descriptors whose meaning is more specific than "Neuroblastoma".
This graph shows the total number of publications written about "Neuroblastoma" by people in this website by year, and whether "Neuroblastoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 1 | 0 | 1 | | 1993 | 1 | 2 | 3 | | 1994 | 1 | 0 | 1 | | 1995 | 2 | 1 | 3 | | 1996 | 4 | 3 | 7 | | 1998 | 1 | 2 | 3 | | 1999 | 0 | 3 | 3 | | 2000 | 1 | 1 | 2 | | 2001 | 2 | 2 | 4 | | 2003 | 1 | 2 | 3 | | 2004 | 3 | 0 | 3 | | 2005 | 2 | 1 | 3 | | 2006 | 7 | 4 | 11 | | 2007 | 5 | 3 | 8 | | 2008 | 3 | 1 | 4 | | 2009 | 5 | 1 | 6 | | 2010 | 5 | 0 | 5 | | 2011 | 2 | 0 | 2 | | 2012 | 1 | 3 | 4 | | 2013 | 2 | 1 | 3 | | 2014 | 1 | 2 | 3 | | 2015 | 2 | 0 | 2 | | 2016 | 1 | 1 | 2 | | 2017 | 3 | 2 | 5 | | 2018 | 3 | 3 | 6 | | 2019 | 1 | 1 | 2 | | 2020 | 3 | 0 | 3 | | 2021 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Neuroblastoma" by people in Profiles.
-
Slatnick LR, Jimeno A, Gore L, Macy ME. Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma. Drugs Today (Barc). 2021 Nov; 57(11):677-688.
-
Bates PD, Rakhmilevich AL, Cho MM, Bouchlaka MN, Rao SL, Hales JM, Orentas RJ, Fry TJ, Gilles SD, Sondel PM, Capitini CM. Combining Immunocytokine and Ex Vivo Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2+ Murine Neuroblastoma. Front Immunol. 2021; 12:668307.
-
Li Z, Wang-Heaton H, Cartwright BM, Makinwa Y, Hilton BA, Musich PR, Shkriabai N, Kvaratskhelia M, Guan S, Chen Q, Yu X, Zou Y. ATR prevents Ca2+ overload-induced necrotic cell death through phosphorylation-mediated inactivation of PARP1 without DNA damage signaling. FASEB J. 2021 05; 35(5):e21373.
-
Raitio A, Rice MJ, Mullassery D, Losty PD. Stage 4S Neuroblastoma: What Are the Outcomes? A Systematic Review of Published Studies. Eur J Pediatr Surg. 2021 Oct; 31(5):385-389.
-
Bellary A, Villarreal A, Eslami R, Undseth QJ, Lec B, Defnet AM, Bagrodia N, Kandel JJ, Borden MA, Shaikh S, Chopra R, Laetsch TW, Delaney LJ, Shaw CM, Eisenbrey JR, Hernandez SL, Sirsi SR. Perfusion-guided sonopermeation of neuroblastoma: a novel strategy for monitoring and predicting liposomal doxorubicin uptake in vivo. Theranostics. 2020; 10(18):8143-8161.
-
Gurria JP, Malek MM, Heaton TE, Gehred A, Lautz TB, Rhee DS, Tracy ET, Grant CN, Baertshiger RM, Bruny J, Christison-Lagay ER, Rodeberg DA, Ehrlich PF, Dasgupta R, Aldrink JH. Minimally invasive surgery for abdominal and thoracic neuroblastic tumors: A systematic review by the APSA Cancer committee. J Pediatr Surg. 2020 Nov; 55(11):2260-2272.
-
Zeineldin M, Federico S, Chen X, Fan Y, Xu B, Stewart E, Zhou X, Jeon J, Griffiths L, Nguyen R, Norrie J, Easton J, Mulder H, Yergeau D, Liu Y, Wu J, Van Ryn C, Naranjo A, Hogarty MD, Kaminski MM, Valentine M, Pruett-Miller SM, Pappo A, Zhang J, Clay MR, Bahrami A, Vogel P, Lee S, Shelat A, Sarthy JF, Meers MP, George RE, Mardis ER, Wilson RK, Henikoff S, Downing JR, Dyer MA. MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nat Commun. 2020 02 14; 11(1):913.
-
Kuzyk CL, Anderson CC, Roede JR. Simvastatin Induces Delayed Apoptosis Through Disruption of Glycolysis and Mitochondrial Impairment in Neuroblastoma Cells. Clin Transl Sci. 2020 05; 13(3):563-572.
-
Rokita JL, Rathi KS, Cardenas MF, Upton KA, Jayaseelan J, Cross KL, Pfeil J, Egolf LE, Way GP, Farrel A, Kendsersky NM, Patel K, Gaonkar KS, Modi A, Berko ER, Lopez G, Vaksman Z, Mayoh C, Nance J, McCoy K, Haber M, Evans K, McCalmont H, Bendak K, Böhm JW, Marshall GM, Tyrrell V, Kalletla K, Braun FK, Qi L, Du Y, Zhang H, Lindsay HB, Zhao S, Shu J, Baxter P, Morton C, Kurmashev D, Zheng S, Chen Y, Bowen J, Bryan AC, Leraas KM, Coppens SE, Doddapaneni H, Momin Z, Zhang W, Sacks GI, Hart LS, Krytska K, Mosse YP, Gatto GJ, Sanchez Y, Greene CS, Diskin SJ, Vaske OM, Haussler D, Gastier-Foster JM, Kolb EA, Gorlick R, Li XN, Reynolds CP, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB, Raman P, Wheeler DA, Maris JM. Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Rep. 2019 11 05; 29(6):1675-1689.e9.
-
Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 12 01; 37(34):3243-3255.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|